Academia

Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.

When seniors with cancer are being treated with combination therapies, providers need to keep in mind more than just the complex regimens they’re administering, said Ginah Nightingale, PharmD, associate professor of pharmacy practice at Jefferson College of Pharmacy.

Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.

For 34 years, Ochsner Health System has annually recognized scientists who have made major contributions regarding the relationship between smoking and disease along with the development of innovative treatment modalities.

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Value-based programs such as accountable care organizations appear to encourage the adoption and spread of care coordination activities by hospitals.

The survey aimed to better understand the perceptions, experiences, and educational needs of patients who have nonmotor symptoms of Parkinson disease as well as their caregivers.

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.

This study explores the causes of emotionally adverse patient experiences in cancer care and presents a taxonomy for analyzing free-text patient data.

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not appear to affect patient-reported chronic obstructive pulmonary disease (COPD) symptom scores.